BACKGROUND: Subclinical thyroid dysfunction is associated with increased mortality and cardiovascular risk. It is unknown whether this association remains within normal thyroid function range. METHODS: The study was conducted using the computerized database of the Sharon-Shomron district of Clalit Health services. Included were subjects aged ≥40 years with normal thyroid function. Patients with a history of thyroid or cardiovascular diseases or diabetes were excluded. The primary end points were all-cause mortality and the need for coronary revascularization with either percutaneous coronary intervention or coronary artery bypass grafting. RESULTS: The 42,149 participants were stratified into 3 groups of equal thyrotropin intervals (0.35-1.6, 1.7-2.9, and 3-4.2 mIU/L). During a mean follow-up of 4.5±2.1 years, 4239 (10.1%) participants died and 1575 (3.7%) underwent coronary revascularization. For both women and men, the lowest mortality rates were observed in the intermediate thyrotropin group. Nevertheless, only for the low thyrotropin group, mortality risk remained significantly higher as compared with the intermediate thyrotropin group, even following multivariate model adjusted for the conventional cardiovascular risk factors, in both women (odds ratio 1.22; 95% confidence interval, 1.09-1.36 for the low thyrotropin group, compared with the intermediate group) and men (odds ratio 1.14; 95% confidence interval, 1.01-1.3 for the low thyrotropin group, compared with the intermediate group). There was no significant difference in the need for coronary revascularization among the 3 thyrotropin groups in both men and women. CONCLUSIONS: Low thyrotropin level within the reference range is associated with increased risk for all-cause mortality.
BACKGROUND: Subclinical thyroid dysfunction is associated with increased mortality and cardiovascular risk. It is unknown whether this association remains within normal thyroid function range. METHODS: The study was conducted using the computerized database of the Sharon-Shomron district of Clalit Health services. Included were subjects aged ≥40 years with normal thyroid function. Patients with a history of thyroid or cardiovascular diseases or diabetes were excluded. The primary end points were all-cause mortality and the need for coronary revascularization with either percutaneous coronary intervention or coronary artery bypass grafting. RESULTS: The 42,149 participants were stratified into 3 groups of equal thyrotropin intervals (0.35-1.6, 1.7-2.9, and 3-4.2 mIU/L). During a mean follow-up of 4.5±2.1 years, 4239 (10.1%) participants died and 1575 (3.7%) underwent coronary revascularization. For both women and men, the lowest mortality rates were observed in the intermediate thyrotropin group. Nevertheless, only for the low thyrotropin group, mortality risk remained significantly higher as compared with the intermediate thyrotropin group, even following multivariate model adjusted for the conventional cardiovascular risk factors, in both women (odds ratio 1.22; 95% confidence interval, 1.09-1.36 for the low thyrotropin group, compared with the intermediate group) and men (odds ratio 1.14; 95% confidence interval, 1.01-1.3 for the low thyrotropin group, compared with the intermediate group). There was no significant difference in the need for coronary revascularization among the 3 thyrotropin groups in both men and women. CONCLUSIONS: Low thyrotropin level within the reference range is associated with increased risk for all-cause mortality.
Authors: Marcus Dörr; Daniel M Robinson; Henri Wallaschofski; Christian Schwahn; Ulrich John; Stephan B Felix; Henry Völzke Journal: J Clin Endocrinol Metab Date: 2005-11-22 Impact factor: 5.958
Authors: Faizel Osman; Jayne A Franklyn; Roger L Holder; Michael C Sheppard; Michael D Gammage Journal: J Am Coll Cardiol Date: 2006-12-13 Impact factor: 24.094
Authors: Anne R Cappola; Linda P Fried; Alice M Arnold; Mark D Danese; Lewis H Kuller; Gregory L Burke; Russell P Tracy; Paul W Ladenson Journal: JAMA Date: 2006-03-01 Impact factor: 56.272
Authors: Marcus Dörr; Birger Wolff; Daniel M Robinson; Ulrich John; Jan Lüdemann; Wieland Meng; Stephan B Felix; Henry Völzke Journal: J Clin Endocrinol Metab Date: 2004-11-02 Impact factor: 5.958
Authors: Nicolas Ochs; Reto Auer; Douglas C Bauer; David Nanchen; Jacobijn Gussekloo; Jacques Cornuz; Nicolas Rodondi Journal: Ann Intern Med Date: 2008-05-19 Impact factor: 25.391
Authors: Bjørn O Åsvold; Lars J Vatten; Trine Bjøro; Douglas C Bauer; Alexandra Bremner; Anne R Cappola; Graziano Ceresini; Wendy P J den Elzen; Luigi Ferrucci; Oscar H Franco; Jayne A Franklyn; Jacobijn Gussekloo; Giorgio Iervasi; Misa Imaizumi; Patricia M Kearney; Kay-Tee Khaw; Rui M B Maciel; Anne B Newman; Robin P Peeters; Bruce M Psaty; Salman Razvi; José A Sgarbi; David J Stott; Stella Trompet; Mark P J Vanderpump; Henry Völzke; John P Walsh; Rudi G J Westendorp; Nicolas Rodondi Journal: JAMA Intern Med Date: 2015-06 Impact factor: 21.873
Authors: Anne R Cappola; Alice M Arnold; Kendra Wulczyn; Michelle Carlson; John Robbins; Bruce M Psaty Journal: J Clin Endocrinol Metab Date: 2014-12-16 Impact factor: 5.958
Authors: Arjola Bano; Klodian Dhana; Layal Chaker; Maryam Kavousi; M Arfan Ikram; Francesco U S Mattace-Raso; Robin P Peeters; Oscar H Franco Journal: JAMA Intern Med Date: 2017-11-01 Impact factor: 21.873
Authors: Nicolien A van Vliet; Evie van der Spoel; Marian Beekman; P Eline Slagboom; Gerard Jan Blauw; Jacobijn Gussekloo; Rudi G J Westendorp; Diana van Heemst Journal: Aging (Albany NY) Date: 2017-10-25 Impact factor: 5.682